Tebentafusp in Molecular Relapsed Disease (MRD) Melanoma
Status:
Not yet recruiting
Trial end date:
2026-06-30
Target enrollment:
Participant gender:
Summary
Researchers are trying to find ways to improve the management of people with intermediate or
high risk resected cutaneous melanoma or with primary uveal melanoma.
This research study is investigating using a new blood test to decide when to give a drug
called tebentafusp. Tebentafusp has been used in clinical trials in patients with advanced
cutaneous and uveal melanoma. This study is designed to determine if tebentafusp can help
patients with cutaneous or uveal melanoma live longer.